ESMO 2022 | SURPASS: ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy

David Hong, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shared updated safety and efficacy of the Phase I SURPASS (NCT04044859) trial investigating ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors positive for the cancer testis antigen melanoma-associated antigen A4 (MAGE-A4). Safety, efficacy, pharmacokinetics, pharmacodynamics, and tumor biopsy characterization are being evaluated. Overall response rate (ORR) was 31%, disease control rate (DCR) was 75.9%. Overall, ADP-A2M4CD8 continued to demonstrate a favorable benefit to risk profile in multiple MAGE-A4+ unresectable or metastatic tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.